Yanping Xu

4.1k total citations · 1 hit paper
46 papers, 2.7k citations indexed

About

Yanping Xu is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Yanping Xu has authored 46 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 11 papers in Oncology and 9 papers in Epidemiology. Recurrent topics in Yanping Xu's work include Epigenetics and DNA Methylation (11 papers), Metabolism, Diabetes, and Cancer (6 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Yanping Xu is often cited by papers focused on Epigenetics and DNA Methylation (11 papers), Metabolism, Diabetes, and Cancer (6 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Yanping Xu collaborates with scholars based in China, United States and United Kingdom. Yanping Xu's co-authors include Yue Xiong, Lei Lv, Kun‐Liang Guan, Qun‐Ying Lei, Tingting Li, Xin Zhou, Ying Liu, Gang Wang, Di Zhao and Li Dong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Yanping Xu

42 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1

2022 160 citations Ruonan Zhang, Yajing Yang et al. Proceedings of the National Academy of Sciences profile →

Peers

Yanping Xu

ONCOL

EPIDE

IMMUN

Mario P. Tschan Switzerland

Ling‐Wen Ding Singapore

Cheng Ean Chee Singapore

Jingxuan Pan China

Cheng-Yang Chou Taiwan

Chunrong Yu United States

Haiming Dai China

Hayato Hikita Japan

Luca Quagliata Switzerland

Fernando Vidal‐Vanaclocha Spain

Mario P. Tschan Switzerland

Yanping Xu

2.2k ×1.3

767 ×1.3

ONCOL

753 ×1.4

1.1k ×2.2

EPIDE

407 ×1.2

IMMUN

Citations per year, relative to Yanping Xu Yanping Xu (= 1×) peers Mario P. Tschan

Countries citing papers authored by Yanping Xu

Since Specialization

Citations

This map shows the geographic impact of Yanping Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanping Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanping Xu more than expected).

Fields of papers citing papers by Yanping Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanping Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanping Xu. The network helps show where Yanping Xu may publish in the future.

Co-authorship network of co-authors of Yanping Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Yanping Xu. A scholar is included among the top collaborators of Yanping Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanping Xu. Yanping Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Xinchao, Xinyu Zhao, Kai Wang, et al.. (2025). HNF4α-TET2-FBP1 axis contributes to gluconeogenesis and type 2 diabetes. eLife. 13.

Yin, Xiaomao, Midie Xu, Tongguan Tian, et al.. (2025). Immune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target. Molecular Cancer. 25(1).

Lin, Mingen, Fei Teng, Yan Ma, et al.. (2025). TET2 orchestrates YAP signaling to potentiate targetable vulnerability in hepatocellular carcinoma. Cell Death and Disease. 16(1). 438–438.

Zhang, Xinchao, Xinyu Zhao, Kai Wang, et al.. (2024). HNF4α-TET2-FBP1 axis contributes to gluconeogenesis and type 2 diabetes. eLife. 13. 1 indexed citations

Dong, Wenjing, Mingen Lin, Ruonan Zhang, et al.. (2024). d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity. Cancer Letters. 591. 216883–216883. 6 indexed citations

He, Jing, et al.. (2023). D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC. Oncogene. 42(47). 3503–3513. 4 indexed citations

Chen, Xuemei, et al.. (2023). Efficacy of the long‐acting gonadotropin‐releasing hormone agonist long protocol on IVF/ICSI outcomes of patients with repeated implantation failure. International Journal of Gynecology & Obstetrics. 164(2). 563–570. 1 indexed citations

He, Jing, Mingen Lin, Xinchao Zhang, et al.. (2023). TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential. Cell Discovery. 9(1). 84–84. 9 indexed citations

Tian, Tongguan, Wanwan Yi, Yixin Xu, et al.. (2023). FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell Reports. 42(11). 113362–113362. 13 indexed citations

10.

Lin, Mingen, Jing He, Wenjing Dong, et al.. (2023). Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma. Journal of Clinical Investigation. 133(9). 38 indexed citations

11.

Zhang, Ruonan, Yajing Yang, Wenjing Dong, et al.. (2022). D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proceedings of the National Academy of Sciences. 119(8). 160 indexed citations breakdown →

12.

Li, Shuyan, Jing He, Ruonan Zhang, et al.. (2022). TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. Cancer Research. 82(11). 2097–2109. 34 indexed citations

13.

Wang, Qun, Yen‐Yu Lin, Baojun Zhang, et al.. (2020). A mosaic analysis system with Cre or Tomato expression in the mouse. Proceedings of the National Academy of Sciences. 117(45). 28212–28220. 3 indexed citations

14.

Smith, Matthew D., Lei Lv, Tadashi Nakagawa, et al.. (2020). USP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2. Science Advances. 6(38). 37 indexed citations

15.

Xu, Yanping, Lei Lv, Ying Liu, et al.. (2019). Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. Journal of Clinical Investigation. 129(10). 4316–4331. 181 indexed citations

16.

Xu, Yanping, Fulong Li, Lei Lv, et al.. (2014). Oxidative Stress Activates SIRT2 to Deacetylate and Stimulate Phosphoglycerate Mutase. Cancer Research. 74(13). 3630–3642. 128 indexed citations

17.

Liu, Yao-Bin, Danhong Shen, Paul R. Gavine, et al.. (2014). HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. British Journal of Cancer. 110(5). 1169–1178. 91 indexed citations

18.

Li, Tingting, Mengxi Liu, Xu Feng, et al.. (2013). Glyceraldehyde-3-phosphate Dehydrogenase Is Activated by Lysine 254 Acetylation in Response to Glucose Signal. Journal of Biological Chemistry. 289(6). 3775–3785. 77 indexed citations

19.

Liu, Chen‐Ying, Tingting Li, Yanping Xu, et al.. (2010). PP1 Cooperates with ASPP2 to Dephosphorylate and Activate TAZ. Journal of Biological Chemistry. 286(7). 5558–5566. 111 indexed citations

20.

Sinclair, Simon, Inge De Lepeleire, Stefanie A. Kane, et al.. (2007). MK-0974, a novel oral CGRP antagonist, exhibits similar pharmacokinetics during and between migraine attacks. Headache The Journal of Head and Face Pain. 47(5). 811–812. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact